# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and raises the price target f...
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of ...
Craig-Hallum analyst Christian Schwab initiates coverage on Maravai LifeSciences (NASDAQ:MRVI) with a Buy rating and announc...